Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD, also known as p110δ) is a class IA phosphoinositide 3-kinase (PI3K) catalytic subunit predominantly expressed in leukocytes. It plays a critical role in the development, differentiation, and activation of B and T lymphocytes by generating the second messenger phosphatidylinositol 3,4,5-trisphosphate (PIP3), which activates downstream AKT/mTOR signaling pathways. Dysregulation of PIK3CD is heavily implicated in human diseases; somatic gain-of-function mutations or overexpression are associated with hematological malignancies such as chronic lymphocytic leukemia (CLL) and various lymphomas, while germline gain-of-function mutations cause Activated PI3K-delta Syndrome (APDS), a primary immunodeficiency characterized by lymphoproliferation and recurrent infections.\n\nConsequently, PIK3CD has emerged as a major therapeutic target. Small-molecule inhibitors, such as idelalisib and leniolisib, are designed to selectively block its kinase activity to treat lymphomas and APDS, respectively. However, therapeutic targeting of PIK3CD is associated with significant safety challenges, including severe immune-mediated toxicities like colitis, hepatotoxicity, and pneumonitis, which are largely driven by the depletion of regulatory T cells.
Phosphatidylinositol 3-kinase delta inhibitor
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform (PIK3CD).